Skip to main content

Table 3 Univariate logistic regression analysis for the association between clinical features and emergence of rtA181T mutation in LAM-resistant patients

From: Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B

Clinical factors

rtA181T

OR (95%CI)

P Value

 

Yes (n = 10)

No (n = 113)

  

Sex (male)

10 (100%)

91 (80.5%)

> 106 (0-> 106)

0.998

Age (years)

58.5 ± 8.3

45.7 ± 10.1

1.144 (1.056-1.240)

0.001a

rtM204V

2 (20.0%)

42 (37.2%)

1.582 (0.423-5.909)

0.495

rtM204I

4 (40.0%)

58 (51.3%)

2.366 (0.480-11.670)

0.290

rtM204V+I

4 (40.0%)

13 (11.5%)

5.128 (1.276-20.607)

0.021

rtL180M

3 (30.0%)

31 (27.4%)

1.134 (0.276-4.663)

0.862

HBeAg

2 (20.0%)

63 (55.8%)

0.198 (0.040-0.976)

0.047

HBV-DNA (106 copies/mL)

15 (0.0015-16063)

2.08 (0.001-4640)

1.000 (0.999-1.001)

0.688

AST (IU/L)

147.0 ± 220.2

114.1 ± 122.1

0.999 (0.996-1.003)

0.693

ALT (IU/L)

217.3 ± 335.9

124.7 ± 124.7

0.999 (0.995-1.002)

0.408

Alpha-fetoprotein (ng/dL)

3 (0-18)

4 (0-17)

0.998 (0.997-1.001)

0.876

BCP mutation

7 (70.0%)

52 (46.0%)

2.737 (0.674-11.124)

0.159

Precore stop codon mutation

4 (40.0%)

52 (46.0%)

0.782 (0.209-2.922)

0.715

Genotype C

4 (40.0%)

35 (31.0%)

1.486 (0.394-5.598)

0.559

Pre-S internal deletions

3 (30.0%)

29 (25.7%)

2.024 (0.532-7.693)

0.301

Cirrhosis

8 (80.0%)

32 (28.3%)

10.125 (2.039-50.281)

0.005

Duration of LAM treatment (months)

13 (6-55)

13.5 (6-48)

1.043 (0.990-1.099)

0.117

  1. Values were given as either mean ± SD, median (range) or number (%).
  2. aAccording to the method of Bonferroni correction for multiple comparisons, P < 0.0029 was considered statistically significant.